Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI

A meta-analysis of randomised controlled trials

Umesh Tamhane, Pascal Meier, Stanley Chetcuti, Kang Yin Chen, Seung-Woon Rha, Michael P. Grossman, Hitinder Gurm

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Aims: Cilostazol has been associated with reduction in restenosis in patients undergoing coronary and peripheral arterial angioplasty. Our objective was to evaluate the impact of cilostazol on restenosis in patients undergoing contemporary PCI with bare metal (BMS) or drug eluting stents (DES) and treated with aspirin and thienopyridine. Methods and results: Ten randomised trials (n=2,809 patients) comparing triple antiplatelet therapy (aspirin, thienopyridine and cilostazol) with standard dual antiplatelet therapy were included. Summary risk ratios for restenosis, late loss, target lesion revascularisation (TLR) and target vessel revascularisation (TVR) were calculated using fixed-effects models. Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0.24 mm, 95% CI 0.15-0.33, p<0.001) and DES groups (mean difference 0.12 mm, 95% CI 0.07-0.18, p<0.001). Cilostazol therapy was associated with a significant reduction in angiographic restenosis (Odds ratio [OR] 0.52, 95% CI 0.41- 0.66, p<0.001) with consistent benefits in patients treated with BMS (OR 0.49, 95% CI 0.35-0.70, p<0.001) or DES (OR 0.54, 95% CI 0.38-0.76, p=0.001). Addition of cilostazol to dual antiplatelet therapy was associated with a significant reduction in TLR (OR 0.38, 95% CI 0.25-0.58, p<0.001), with no difference in subacute stent thrombosis (OR 1.91, 95% CI 0.33-11.08, p=0.47), or major bleeding (OR 0.87, 95% CI 0.44-1.74, P=0.69) but with an increased risk of skin rash (OR 3.67, 95% CI 1.86-7.24, p<0.001). Conclusions: Cilostazol in addition to dual antiplatelet therapy is associated with a reduction in angiographic restenosis in patients undergoing stent based PCI. This inexpensive drug may be particularly beneficial in patients who are at high risk of restenosis and it should undergo further evaluation in large, definitive randomised controlled trials.

Original languageEnglish
Pages (from-to)384-393
Number of pages10
JournalEuroIntervention
Volume5
Issue number3
DOIs
Publication statusPublished - 2009 Aug 1

Fingerprint

Stents
Meta-Analysis
Randomized Controlled Trials
Odds Ratio
Drug-Eluting Stents
Aspirin
Therapeutics
cilostazol
Exanthema
Angioplasty
Thrombosis
Metals
Hemorrhage
Pharmaceutical Preparations

Keywords

  • Angioplasty
  • Cilostazol
  • Coronary flow
  • Drug delivery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI : A meta-analysis of randomised controlled trials. / Tamhane, Umesh; Meier, Pascal; Chetcuti, Stanley; Chen, Kang Yin; Rha, Seung-Woon; Grossman, Michael P.; Gurm, Hitinder.

In: EuroIntervention, Vol. 5, No. 3, 01.08.2009, p. 384-393.

Research output: Contribution to journalArticle

Tamhane, Umesh ; Meier, Pascal ; Chetcuti, Stanley ; Chen, Kang Yin ; Rha, Seung-Woon ; Grossman, Michael P. ; Gurm, Hitinder. / Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI : A meta-analysis of randomised controlled trials. In: EuroIntervention. 2009 ; Vol. 5, No. 3. pp. 384-393.
@article{b1612d42b7ac4d148f0069888f618a74,
title = "Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: A meta-analysis of randomised controlled trials",
abstract = "Aims: Cilostazol has been associated with reduction in restenosis in patients undergoing coronary and peripheral arterial angioplasty. Our objective was to evaluate the impact of cilostazol on restenosis in patients undergoing contemporary PCI with bare metal (BMS) or drug eluting stents (DES) and treated with aspirin and thienopyridine. Methods and results: Ten randomised trials (n=2,809 patients) comparing triple antiplatelet therapy (aspirin, thienopyridine and cilostazol) with standard dual antiplatelet therapy were included. Summary risk ratios for restenosis, late loss, target lesion revascularisation (TLR) and target vessel revascularisation (TVR) were calculated using fixed-effects models. Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0.24 mm, 95{\%} CI 0.15-0.33, p<0.001) and DES groups (mean difference 0.12 mm, 95{\%} CI 0.07-0.18, p<0.001). Cilostazol therapy was associated with a significant reduction in angiographic restenosis (Odds ratio [OR] 0.52, 95{\%} CI 0.41- 0.66, p<0.001) with consistent benefits in patients treated with BMS (OR 0.49, 95{\%} CI 0.35-0.70, p<0.001) or DES (OR 0.54, 95{\%} CI 0.38-0.76, p=0.001). Addition of cilostazol to dual antiplatelet therapy was associated with a significant reduction in TLR (OR 0.38, 95{\%} CI 0.25-0.58, p<0.001), with no difference in subacute stent thrombosis (OR 1.91, 95{\%} CI 0.33-11.08, p=0.47), or major bleeding (OR 0.87, 95{\%} CI 0.44-1.74, P=0.69) but with an increased risk of skin rash (OR 3.67, 95{\%} CI 1.86-7.24, p<0.001). Conclusions: Cilostazol in addition to dual antiplatelet therapy is associated with a reduction in angiographic restenosis in patients undergoing stent based PCI. This inexpensive drug may be particularly beneficial in patients who are at high risk of restenosis and it should undergo further evaluation in large, definitive randomised controlled trials.",
keywords = "Angioplasty, Cilostazol, Coronary flow, Drug delivery",
author = "Umesh Tamhane and Pascal Meier and Stanley Chetcuti and Chen, {Kang Yin} and Seung-Woon Rha and Grossman, {Michael P.} and Hitinder Gurm",
year = "2009",
month = "8",
day = "1",
doi = "10.4244/V5I3A60",
language = "English",
volume = "5",
pages = "384--393",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "3",

}

TY - JOUR

T1 - Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI

T2 - A meta-analysis of randomised controlled trials

AU - Tamhane, Umesh

AU - Meier, Pascal

AU - Chetcuti, Stanley

AU - Chen, Kang Yin

AU - Rha, Seung-Woon

AU - Grossman, Michael P.

AU - Gurm, Hitinder

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Aims: Cilostazol has been associated with reduction in restenosis in patients undergoing coronary and peripheral arterial angioplasty. Our objective was to evaluate the impact of cilostazol on restenosis in patients undergoing contemporary PCI with bare metal (BMS) or drug eluting stents (DES) and treated with aspirin and thienopyridine. Methods and results: Ten randomised trials (n=2,809 patients) comparing triple antiplatelet therapy (aspirin, thienopyridine and cilostazol) with standard dual antiplatelet therapy were included. Summary risk ratios for restenosis, late loss, target lesion revascularisation (TLR) and target vessel revascularisation (TVR) were calculated using fixed-effects models. Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0.24 mm, 95% CI 0.15-0.33, p<0.001) and DES groups (mean difference 0.12 mm, 95% CI 0.07-0.18, p<0.001). Cilostazol therapy was associated with a significant reduction in angiographic restenosis (Odds ratio [OR] 0.52, 95% CI 0.41- 0.66, p<0.001) with consistent benefits in patients treated with BMS (OR 0.49, 95% CI 0.35-0.70, p<0.001) or DES (OR 0.54, 95% CI 0.38-0.76, p=0.001). Addition of cilostazol to dual antiplatelet therapy was associated with a significant reduction in TLR (OR 0.38, 95% CI 0.25-0.58, p<0.001), with no difference in subacute stent thrombosis (OR 1.91, 95% CI 0.33-11.08, p=0.47), or major bleeding (OR 0.87, 95% CI 0.44-1.74, P=0.69) but with an increased risk of skin rash (OR 3.67, 95% CI 1.86-7.24, p<0.001). Conclusions: Cilostazol in addition to dual antiplatelet therapy is associated with a reduction in angiographic restenosis in patients undergoing stent based PCI. This inexpensive drug may be particularly beneficial in patients who are at high risk of restenosis and it should undergo further evaluation in large, definitive randomised controlled trials.

AB - Aims: Cilostazol has been associated with reduction in restenosis in patients undergoing coronary and peripheral arterial angioplasty. Our objective was to evaluate the impact of cilostazol on restenosis in patients undergoing contemporary PCI with bare metal (BMS) or drug eluting stents (DES) and treated with aspirin and thienopyridine. Methods and results: Ten randomised trials (n=2,809 patients) comparing triple antiplatelet therapy (aspirin, thienopyridine and cilostazol) with standard dual antiplatelet therapy were included. Summary risk ratios for restenosis, late loss, target lesion revascularisation (TLR) and target vessel revascularisation (TVR) were calculated using fixed-effects models. Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0.24 mm, 95% CI 0.15-0.33, p<0.001) and DES groups (mean difference 0.12 mm, 95% CI 0.07-0.18, p<0.001). Cilostazol therapy was associated with a significant reduction in angiographic restenosis (Odds ratio [OR] 0.52, 95% CI 0.41- 0.66, p<0.001) with consistent benefits in patients treated with BMS (OR 0.49, 95% CI 0.35-0.70, p<0.001) or DES (OR 0.54, 95% CI 0.38-0.76, p=0.001). Addition of cilostazol to dual antiplatelet therapy was associated with a significant reduction in TLR (OR 0.38, 95% CI 0.25-0.58, p<0.001), with no difference in subacute stent thrombosis (OR 1.91, 95% CI 0.33-11.08, p=0.47), or major bleeding (OR 0.87, 95% CI 0.44-1.74, P=0.69) but with an increased risk of skin rash (OR 3.67, 95% CI 1.86-7.24, p<0.001). Conclusions: Cilostazol in addition to dual antiplatelet therapy is associated with a reduction in angiographic restenosis in patients undergoing stent based PCI. This inexpensive drug may be particularly beneficial in patients who are at high risk of restenosis and it should undergo further evaluation in large, definitive randomised controlled trials.

KW - Angioplasty

KW - Cilostazol

KW - Coronary flow

KW - Drug delivery

UR - http://www.scopus.com/inward/record.url?scp=70349787228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349787228&partnerID=8YFLogxK

U2 - 10.4244/V5I3A60

DO - 10.4244/V5I3A60

M3 - Article

VL - 5

SP - 384

EP - 393

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 3

ER -